Methods for use of epinephrine fine particles for treatment of conditions responsive to epinephrine
The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.
1. A method of treating a breathing difficulty in a subject in need thereof, the method comprising:
providing a pharmaceutical composition formulated for buccal or sublingual administration comprising approximately 10 mg to approximately 40 mg epinephrine bitartrate microcrystals; and
administering the pharmaceutical composition to the subject to treat the breathing difficulty.
2. The method in accordance with claim 1 , wherein the breathing difficulty is associated with at least one of anaphylaxis, asthma, bronchial asthma, bronchitis, emphysema, and a respiratory infection.
3. A method for treatment of a breathing difficulty in a subject in need thereof, the method comprising:
providing a pharmaceutical composition formulated for buccal or sublingual administration having an active ingredient consisting of 10 mg to 20 mg epinephrine bitartrate microcrystals; and
administering the pharmaceutical composition to the subject to treat the breathing difficulty.
4. The method in accordance with claim 3 , wherein the breathing difficulty is associated with at least one of anaphylaxis, asthma, bronchial asthma, bronchitis, emphysema, and a respiratory infection.
5. A method for treatment of a breathing difficulty in a subject in need thereof, the method comprising:
providing a pharmaceutical composition formulated for buccal or sublingual administration having an active ingredient consisting of 20 mg epinephrine bitartrate microcrystals, the epinephrine bitartrate microcrystals formed from epinephrine bitartrate having been reduced via microfluidization to a particle size of 2.5 μm or less; and
administering the pharmaceutical composition to the subject to treat the breathing difficulty.
6. The method in accordance with claim 3 , wherein the breathing difficulty is associated with at least one of anaphylaxis, asthma, bronchial asthma, bronchitis, emphysema, and a respiratory infection.